LCM
NTGN

Laurion Capital Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Laurion Capital Management’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-39,961
Closed -$341K – 1555
2018
Q3 		$341K Sell
39,961
-85,039
-68% -$943K ﹤0.01% 906
2018
Q2 		$1.57M Buy
+125,000
New +$1.71M 0.01% 661

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Laurion Capital Management's NTGN Position: Q4 2018 in Review

Laurion Capital Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q4 2018, closing a stake of 39,961 shares — an estimated $341K sold.

Laurion Capital Management first reported a position in NTGN in Q2 2018 and held it in 2 quarters. The position peaked at $1.57M in Q2 2018. 44 funds tracked by Wall St. Rank hold NTGN as of Q4 2018.

  • Laurion Capital Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Laurion Capital Management sold 39,961 Neon Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $341K.
  • Laurion Capital Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Laurion Capital Management's Neon Therapeutics, Inc. Common Stock position peaked at $1.57M in Q2 2018.
  • 44 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Laurion Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.